Benitec (BLT)

Shares / Stock Code


Stock Exchange / Sharemarket


Benitec (BLT) is a biotechnology research and development company, involved in developing therapeutics for serious diseases. BLT has developed a technology that uses DNA directed RNA interference (ddRNAi) to trigger the natural gene silencing process. The technology has potential application in the treatment of various diseases, including cancer, HIV, hepatitis C, autoimmune disorders. R&D and clinical operations are centred in California, USA. BLT was listed on the ASX in 1997. In September 2002, the company first demonstrated its gene silencing technology in animals. Subsequently, the company entered into an alliance with Ozgene, aimed at shutting down specifically targeted genes in rats. In 2003, the company signed an agreement with the US-based Tranzyme to market the company's technology in the US.

BLT's proprietary technology has potential application to a range of diseases. Its gene silencing technology has broad application in human therapeutics; biomedical research; and, plat breeding and animal health. Moreover, In 2003, Promega Corporation acquired the worldwide license for BLT's gene silencing technology. BLT competes with other biotechnology research and development companies.

Benitec (BLT) Products and Services

  • Biotechnology, research and development

Benitec (BLT) Locations and Subsidiaries

Benitec Head Office
356 Collins Street, Level 16,
Phone: (03) 9859 9165
Fax: (03) 9859 8827

Benitec (BLT) Share Price

Submitted by ASX Listed Company on 1 March, 2010 - 01:08